FIELD: medicine; therapy; infectology.
SUBSTANCE: group of inventions relates to the field of medicine, namely to therapy and infectology, and is intended for the prevention or treatment of respiratory viral infections. The combined drug for the prevention or treatment of RNA viral infections is made in the form of a solution for inhalation and contains recombinant interferon α2b, lopinavir, remdesivir, amantadine, sodium chloride, ethyl alcohol and tween 80. The components are used in the stated amounts. In a different the embodiment presents a method for the prevention or treatment of RNA viral infection, includes the use of the specified drug in the form of inhalations, which carry out 5 ml of the solution for 10 minutes from 2 to 6 times a day for 1-14 days.
EFFECT: use of the group of inventions provides effective treatment or prevention of respiratory viral infections while reducing the drug load on the patient's body.
4 cl, 2 dwg, 3 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MEFLOQUINE AND COMBINATIONS THEREOF FOR TREATING AND PREVENTING A CORONAVIRUS INFECTION | 2020 |
|
RU2763024C1 |
| METHOD OF TREATING FOCAL AND CAVITARY CHANGES IN LUNGS OF POST-COVID ETIOLOGY | 2023 |
|
RU2809304C1 |
| ANTI-SARS-COV-2 VIRAL AGENT ANTIPROVIR | 2020 |
|
RU2738885C1 |
| METHOD FOR PROTECTION AGAINST CORONAVIRUS INFECTION | 2020 |
|
RU2747467C1 |
| METHOD FOR COVID-19 PNEUMONIA TREATMENT | 2020 |
|
RU2745535C1 |
| APPLICATION OF N,N'-BIS-(2,3-BUTADIENYL)-1,4-DIAMINOBUTANE DIHYDROCHLORIDE (MDL72.527) FOR SUPPRESSING REPLICATION OF SARS-COV-2 VIRUS | 2020 |
|
RU2761565C1 |
| AGENT FOR REDUCING RISK AND RELIEVING SYMPTOMS OF BETA-CORONAVIRUS INFECTION | 2021 |
|
RU2747890C1 |
| 2-(IMIDAZOL-4-YL)-ETHANAMIDE OF PENTANEDIOIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING COVID-19 AND SYMPTOMS THEREOF | 2021 |
|
RU2824607C2 |
| METHODS FOR TREATING INFECTIOUS DISEASES CAUSED BY CORONAVIRUS | 2021 |
|
RU2772701C1 |
| METHODS OF TREATING CORONAVIRUS INFECTIONS | 2021 |
|
RU2825648C1 |
